Zolin

Quick links to important sections

Zolin

Selected form

Method of action: Bactericidal

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zolin

Property Description
Active ingredient Cefazolin (as Cefazolin Sodium)
Form Sterile powder for solution for injection
Pharmacological class Antibiotic (Beta-Lactam, First-generation cephalosporin)
Common use Elimination of bacterial infections
Origin Semi-synthetic

Zolin is a prescription-only medication whose active component, Cefazolin, is utilized to prevent and resolve infections caused by bacteria. Its identity is clearly defined by its classification as a specialized antibiotic designed for administration within professional healthcare environments, functioning as a definitive bactericidal agent.


What Type of Medicine is Zolin? (Identity and Classification)

Zolin is a First-generation cephalosporin, which positions it within the major pharmacological family of Beta-Lactam antibiotics. The drug's primary function is as a bactericidal agent, meaning it actively kills the bacteria directly, a mechanism that has been clinically recognized for decades.

This classification is determined by the specific chemical structure of the Cefazolin molecule. As a first-generation cephalosporin, it possesses a reliable activity profile, making it a critical tool for use in the perioperative setting for infection prophylaxis, a key role in clinical practice.


Cefazolin: Composition, Origin, and Pharmaceutical Form

The medicine is a single-ingredient product where the active substance is Cefazolin, typically prepared as Cefazolin Sodium. This compound is categorized as a semi-synthetic antibiotic, meaning its structure is chemically derived from the natural cephalosporin base to enhance stability and effectiveness.

The physical form of the preparation is a sterile powder for solution for injection. This powder must be reconstituted with an aqueous solvent before being administered via the parenteral route, such as an intravenous or intramuscular injection. This specific parenteral formulation is engineered to ensure rapid and reliable delivery of Cefazolin into the patient's system.


How Does Zolin Generally Help the Body? (High-Level Purpose)

The fundamental purpose of Zolin is to provide a decisive method for the rapid elimination of bacterial pathogens and susceptible microorganisms. This definitive action is achieved by Cefazolin interfering with the bacteria's protective structural components. By killing the source of the infection, the drug helps the body recover from the illness. It is important to note that Zolin provides no benefit against infections caused by viruses, fungi, or other non-bacterial sources.

Regulatory References

  1. NCBI Bookshelf - NIH

What side effects are possible with Zolin?

Possible Side Effects and Safety Information

The official safety profile of Zolin (Cefazolin) outlines the possible adverse reactions by system-organ class and identifies serious, clinically significant events. The most frequently documented effects often involve the Gastrointestinal system, presenting as nausea, vomiting, or diarrhea, and Immunological systems, appearing as skin rash or urticaria.


System-Organ Classes and Associated Reactions

Adverse reactions are documented across several physiological systems in regulatory texts:

  • Gastrointestinal Disorders: Nausea, Vomiting, Diarrhea, and severe colitis, including the risk of Clostridioides difficile-associated Diarrhea (CDAD).
  • Blood Disorders: Changes in blood cell counts such as leukopenia (low white cells) or thrombocytopenia (low platelets).
  • Local Reactions: Pain, induration (hardening), or phlebitis (vein inflammation) at the injection site.
  • Hepatic/Renal: Transient elevations in liver enzymes and reports of increased BUN/creatinine, indicating potential kidney impact.

Serious Adverse Reactions and Safety Constraints

The regulatory documentation highlights events classified as serious:

  • Serious Hypersensitivity: Immediate and severe allergic reactions, such as anaphylaxis, have been reported and may rarely be fatal.
  • Seizures: These may occur, particularly in individuals with pre-existing impaired renal function due to drug accumulation.

Safety notes specify that individuals with a history of penicillin allergy may have a risk of cross-hypersensitivity. Furthermore, prolonged use of Zolin may result in the overgrowth of non-susceptible organisms (superinfection). Symptoms of CDAD may also occur during or after treatment completion. The medicine is formally contraindicated in patients with a history of immediate hypersensitivity to Cefazolin, cephalosporins, or other Beta-lactam antibiotics.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile of Cefazolin (Zolin) by identifying a clear risk of severe systemic toxicity, primarily involving the Central Nervous System (CNS).

Documented Manifestations and Risks

Category Regulatory Statements
Primary Manifestation The most significant documented clinical sign of overexposure is the occurrence of seizures (convulsions). Other accompanying symptoms may include nausea, vomiting, and diarrhea.
High-Risk Population Patients with impaired renal function (Creatinine Clearance below 55 mL/min) are explicitly identified as being at increased risk for toxicity and seizures due to reduced drug clearance.
Management Principle The management approach is defined as symptomatic and supportive treatment. No specific antidote is known. Anticonvulsant therapy may be administered if seizures occur.

Mandated Emergency Action

In the event of suspected overexposure or the manifestation of severe neurological symptoms, such as seizures or collapse, the medication must be immediately discontinued. Regulatory guidance mandates seeking immediate medical attention for these life-threatening events. Urgent medical help is required for any sign of a seizure or severe difficulty breathing, which indicates acute toxicity.

The official profile directs attention to patients with impaired kidney function, who are explicitly at a higher risk for this severe adverse outcome. Consequently, the core regulatory instruction is an unambiguous mandate to seek urgent medical help and provide immediate symptomatic and supportive care if these signs appear.

Therapeutic Uses of Zolin

Zolin is generally applied to provide supportive relief for conditions where patients experience intense anxiety and fear. The medication is used in situations involving certain distressing symptoms across domains where additional symptomatic support is needed.

Easing Symptoms of Generalized Anxiety

This medicine is commonly used across conditions presenting with episodic or fluctuating manifestations, and may assist in addressing symptom clusters that may become intense or disruptive, such as persistent worry and restlessness. It may assist with maintaining functional stability, which supports general well-being during symptomatic phases.

Management of Acute Panic Episodes

Zolin is applicable within clinical settings that involve acute or disruptive symptom patterns, and is generally relevant for easing symptoms associated with acute or episodic changes, such as those that characterize Panic Disorder. It may support the patient during difficult episodes by easing distress when symptoms become more noticeable.

Quick Fact: Relevant for Symptoms of Increased Tension

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Zolin (Vorinostat)

This section outlines the regulatory classifications for who is eligible to use Zolin, strictly based on governmental labeling and contraindication documents.


Eligibility Classification Population/Condition Regulatory Status
Contraindicated Severe Hepatic Impairment (Child-Pugh C) Prohibited
Restricted Use Mild or Moderate Hepatic Impairment (Child-Pugh A or B) Use with Caution/Dose Reduction Recommended
Special Consideration Pre-existing Hypokalemia or Hypomagnesemia Must be corrected prior to administration
Physiological State Pregnancy Category D (Fetal harm risk)
Physiological State Lactation (Breastfeeding) Use not recommended/Discontinue during therapy
Age Group Pediatric Population Safety and efficacy not established

Eligibility-Context Constraints

Zolin is contraindicated for use in patients diagnosed with severe hepatic impairment. Use in patients with mild or moderate hepatic impairment requires special caution and may necessitate a dosage reduction. The regulatory labeling advises that pre-existing low levels of potassium (hypokalemia) or magnesium (hypomagnesemia) must be corrected before treatment begins. The drug is classified as Pregnancy Category D due to the potential for fetal harm. Female patients who can become pregnant must use effective contraception during and for at least six months after therapy, and breastfeeding is not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the officially documented interaction patterns for Zolin (Cefazolin) as described in regulatory sources.

Pharmacokinetic and Pharmacodynamic Interactions

The co-administration of Zolin with certain other medicines is officially documented to alter the antibiotic’s plasma concentration or increase the risk of specific effects.

  • Probenecid causes a pharmacokinetic interaction by inhibiting the renal excretion of Cefazolin. This results in increased and more prolonged Cefazolin plasma concentrations. Co-administration of these two substances is formally not recommended in prescribing information.
  • Oral Anticoagulants (such as Warfarin) may be associated with a fall in prothrombin activity. For patients receiving co-therapy, official documents note that coagulation monitoring may be required.
  • Co-use with other nephrotoxic agents, such as Aminoglycoside antibiotics, may lead to additive nephrotoxicity (increased risk of kidney toxicity).

Formulations and Procedural Constraints

Interactions also include constraints related to the drug's formulation and specific laboratory procedures:

  • Sodium Content: The parenteral formulation of Cefazolin Sodium contains a documented amount of sodium (approximately 46 mg or 2 mEq per gram of activity). This ingredient content represents a formal consideration for patients maintained on sodium-restricted diets.
  • Laboratory Test: Cefazolin is officially documented to potentially cause a false-positive result on the direct Coombs' test.

Mechanism of Action

Irreversible Targeting of Bacterial Cell Wall Assembly

The mechanism of Zolin (Cefazolin) operates entirely within the biological domain of pathogen structural inhibition. The drug works by acting as a suicide inhibitor that targets and irreversibly binds to specific bacterial enzymes known as Penicillin-Binding Proteins (PBPs). These PBPs are critical for the peptidoglycan synthesis pathway, which builds the strong, supportive cross-links of the bacterial cell wall. This molecular interference inhibits the intended cross-linking of the cell wall, initiating a mechanistic cascade of structural failure.

Cascade of Cell Lysis and Pathogen Elimination

The key pathway effect of Cefazolin's molecular action is the destruction of the microorganism. By blocking the cross-linking, the drug causes the resulting cell wall to be structurally defective, making it unable to withstand the high internal osmotic pressure of the bacteria. The resulting physiological effect is osmotic lysis (rupture), leading directly to the bactericidal (cell-killing) action against susceptible organisms. The mechanism is highly specific, targeting only the bacterial structures.

Mechanism Constraints and Specificity

Cefazolin's activity is constrained by its fundamental reliance on the peptidoglycan cell wall, meaning the mechanism provides no biological effect against non-bacterial pathogens like viruses or fungi. Furthermore, the molecular structure can be entirely overridden by bacterial defenses, primarily the production of beta-lactamase enzymes, which chemically inactivate the drug before it can engage its PBP target.

Dosage and Administration Information

Zolin (Cefazolin) is administered via the parenteral route, typically as an Intravenous (IV) injection or infusion, or as an Intramuscular (IM) injection. Due to the requirement for sterile preparation and specialist administration, the medicine is used exclusively in a professional healthcare setting.

Administration and Dosing

The medicine is supplied as a sterile powder and must be reconstituted with a specified aqueous diluent prior to administration; IV infusions are generally administered slowly over approximately 30 minutes. For standard adult treatment, doses range from 250 mg to 1.5 grams per administration, following a fixed schedule of every 6, 8, or 12 hours based on infection type. The usual maximum daily dose is 6 grams.

For surgical prophylaxis, administration is time-critical. The initial dose is given 1/2 to 1 hour prior to the start of surgery, and the total prophylactic course is typically short, usually discontinued within 24 hours post-surgery. Dosage requires mandatory adjustment for adults with reduced kidney function (renal impairment), based on the calculated Creatinine Clearance, to prevent accumulation. Pediatric dosing is also specified by weight in milligrams per kilogram.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zolin

Evidence for Use in Preventing Surgical Infections (Prophylaxis)

Research has explored the use of Zolin (Cefazolin) for infection prevention in studies, including Randomized Controlled Trials (RCTs), by examining its administration during and after surgery. This evidence describes the administration practices used in studies involving patients undergoing various procedures, such as cardiac, orthopedic, and general surgery. Studies monitored a primary outcome: the rate of Surgical Site Infection (SSI).

Research has found that studies reported measurements of SSI incidence in the observed populations. Pharmacokinetic/Pharmacodynamic (PK/PD) studies have measured Cefazolin concentrations in blood serum and the surgical tissue itself. These findings described drug levels in tissue and serum, which were monitored in relation to target levels used in the studies. What remains unclear is the best characterized administration practice for all patient populations. Research is ongoing, but limited data are still emerging regarding the necessary drug concentrations to achieve target levels at the surgical site in patients with high body weight.


Evidence for Use in Treating Established Infections

Research exploring Zolin's use in the treatment of established bacterial conditions, such as bloodstream, bone, and joint infections, was primarily evaluated in Systematic Reviews and Meta-Analyses of existing data, including retrospective and cohort studies. These studies primarily focused on outcomes related to systemic imbalance, such as All-Cause Mortality and the rate of reported positive clinical changes or bacteriological status. Research explored Cefazolin's use in patient groups with infections caused by susceptible organisms, notably Methicillin-Susceptible Staphylococcus aureus (MSSA).

Research examined comparisons between Cefazolin and other antibiotics in terms of patient outcomes. Reports from observational data described patterns of mortality related to Cefazolin and compared them against alternative antibiotics used for MSSA bloodstream infections. A key limitation is the relative absence of comparative RCTs in certain serious infection contexts, such such as MSSA bacteremia, where current findings describe patterns based mostly on non-randomized data.


What Is Still Uncertain About Zolin Research

Certainty remains low in specific areas of the research. Ongoing scientific discussion continues regarding whether Cefazolin was observed to perform consistently in infections with very high concentrations of bacteria. Research typically focuses on short-term or intermediate outcomes; there is limited information for long-term outcomes and the longevity of the observed clinical or bacteriological status over extended periods.

Key Studies & References

  1. Cefazolin (NCBI Bookshelf - NIH Drug Information)
  2. Cefazolin (MedlinePlus Drug Information)

Frequently Asked Questions (FAQ)

Common questions about Zolin (FAQ)


Q: How long does it typically take for Zolin to start working?

Zolin (Cefazolin) works rapidly by a mechanism classified as bactericidal, meaning it actively kills bacteria by disrupting their protective cell walls. This action begins quickly following administration in a healthcare setting. The drug's mechanism is designed to take effect rapidly by disrupting the bacterial structures.


Q: How quickly does the effect of Zolin wear off after stopping?

Regulatory information indicates that Zolin is cleared from the body relatively quickly. Following an intravenous injection in healthy adults, the drug's serum half-life (the time required for the concentration to reduce by half) is approximately 1.8 hours. Most of the drug (70% to 80%) is excreted, unchanged, in the urine within 24 hours.


Q: Can older adults use Zolin safely?

Official documents note that no major differences in effectiveness or safety have been observed between older adults and younger patients overall. However, because kidney function often decreases with age, a mandatory dose adjustment is required for any adult patient with reduced kidney function. This adjustment helps manage the concentration of the medicine and is a standard consideration for renal impairment.


Q: Is Zolin a medicine that needs to be taken at a specific time of day?

Zolin administration is based on a fixed time interval, such as every 6, 8, or 12 hours, to maintain necessary levels of the medicine in the body. For surgical prophylaxis, the first dose is time-critical and is described as being administered within one hour before the start of surgery.


Q: Are there any major drug categories that always interact with Zolin?

Officially documented interactions include co-administration with probenecid, which is generally not recommended as it increases Zolin concentrations in the blood. Co-use with oral anticoagulants (like warfarin) may require monitoring of coagulation factors, and combining Zolin with other nephrotoxic agents (medicines that can harm the kidneys) may increase the risk of kidney toxicity.


Q: What types of safety monitoring are typically recommended while taking Zolin?

Official documents describe several areas of monitoring that may be considered during treatment. For example, documents suggest monitoring prothrombin time for certain patients (like those on anticoagulants) and general observation for changes in blood cell counts and liver or kidney enzyme levels.


Q: Are there reports of Zolin causing vision problems?

The official product information lists adverse reactions by body system. Ocular or vision-related problems are not commonly or prominently documented among the main reported adverse reactions for Zolin. Most commonly reported effects involve the gastrointestinal and immune systems.


Q: Does the efficacy of Zolin decrease over time?

Official labeling warns that prolonged use of Zolin may result in a condition called superinfection, which is the overgrowth of non-susceptible organisms. The label also cautions against prescribing the drug in the absence of infection to reduce the risk of developing drug-resistant bacteria.


Q: Are there any common foods or supplements that interact with Zolin?

Regulatory documents do not list specific foods or herbal supplements that interact with Zolin. However, the medicine's formulation as Cefazolin Sodium contains a documented amount of sodium. This sodium content is a general consideration for individuals who are managed on a sodium-restricted diet.


Q: Is it safe to take Zolin long-term?

Regulatory texts do not specify a safe maximum duration for long-term treatment. Instead, they focus on the risk of complications from extended use, noting that prolonged use may lead to the overgrowth of non-susceptible organisms (superinfection).


Q: What is the difference between Zolin and a generic version?

The generic version of Zolin is Cefazolin. Regulatory agencies require that a generic medicine contains the same active ingredient (Cefazolin) as the brand name, is identical in strength, and must demonstrate bioequivalence to the brand product. This means the generic must deliver the same amount of active ingredient into the bloodstream in the same amount of time.


Q: Can Zolin be crushed or split?

Zolin is supplied as a sterile powder for solution for injection. It is not formulated as a standard oral tablet. The medicine requires reconstitution with a solvent prior to administration via the parenteral route (injection or infusion) in a professional healthcare setting.


Q: Why might a doctor switch a patient from another medicine to Zolin?

The choice to use Zolin is based on microbiology and susceptibility. Zolin is typically chosen when an infection is proven or strongly suspected to be caused by bacteria that are known to be susceptible (responsive) to Cefazolin. This helps ensure that the correct antibiotic is being used to target the specific pathogen.


Q: Does Zolin have a risk evaluation and mitigation strategy (REMS)?

A Risk Evaluation and Mitigation Strategy (REMS) is a program required by the FDA for certain medicines to ensure their benefits outweigh their risks. Official databases indicate that the FDA has not required Zolin (Cefazolin) to have a formal REMS program beyond the standard regulatory labeling to ensure its safe use.


Q: Is it normal to feel a change in appetite after starting Zolin?

Official safety documents list changes in the gastrointestinal system as possible side effects. Adverse reactions that have been reported include anorexia (a loss of appetite), in addition to the more commonly reported symptoms of nausea and vomiting.


Q: Can Zolin affect the ability to drive or operate machinery?

The label notes that there is a risk of side effects such as dizziness and seizures (particularly in patients with reduced kidney function). Because the drug is administered in a healthcare setting, any effects such as dizziness would be observed by the medical team.


Q: Why might Zolin not work for some people?

Zolin is effective only against bacteria, meaning it provides no benefit against infections caused by viruses, fungi, or other non-bacterial pathogens. Furthermore, some bacteria can produce protective enzymes called beta-lactamase that chemically inactivate the drug before it can target the bacterial cell wall.

How should Zolin be stored and disposed of?

The storage and disposal instructions for Zolin (Cefazolin for Injection) are strictly defined to maintain product quality and safety.

Storage Conditions

Product Form Required Temperature Protection from Light/Moisture
Sterile Powder Controlled Room Temperature (20 C to 25 C) Mandatory
Reconstituted Solution Refrigeration (2 C to 8 C) for extended stability Not applicable

Stability Constraints: The reconstituted solution is stable for 4 hours at room temperature or up to 3 days when refrigerated. Thawed premixed solutions must not be refrozen. The dry powder must be protected from both light and moisture, and the container should be kept tightly closed.

Disposal Requirements: Unused or expired Zolin must be discarded according to official procedures. This includes utilizing a drug take-back program when available, as the medication must not be flushed down the toilet. All medicinal waste must be disposed of in a manner that prevents access by children and pets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zolin found in:

A-Z Index: